BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced that it will be hosting a webinar on April 8 at 11 a.m. ET entitled “Effect of Pregnancy-related Hormones on CYP Induction: Implications for In Vitro ADME-Tox Models.”
“It can be challenging to determine the effects of pregnancy-related hormones on drug pharmacokinetics because pregnancy is usually an exclusion criterion for clinical studies and animal models are not necessarily predictive of human pharmacokinetics. However, a significant number of women need to take at least one medication during their pregnancy and physicians often lack information about how to manage or adjust drug dose recommendations,” said Dr. Chris Black, Senior VP, ADME Tox at BioIVT.
During this webinar, BioIVT Senior Scientist Raju Khatri, MS, PhD, DABT, will discuss his recently published research which shows how pregnancy-related hormones (PRH) are important regulators of hepatic cytochrome P450 (CYP) enzyme expression and function.1 As CYP enzymes play an important role in drug metabolism, altering their expression can change the effectiveness and safety of some drugs.
Using a sandwich-cultured human hepatocyte (SCHH) model, Dr. Khatri’s research team showed that exposure to PRH can significantly increase concentrations of CYP3A4 and other CYPs, resulting in a dose-dependent increase in nifedipine metabolism.1 Nifedipine is a calcium-channel blocker that is often prescribed during pregnancy to manage hypertensive disorder.
“This approach could prove to be a potent addition to conventional in vitro metabolism, toxicity, and disposition studies during drug discovery, and illustrates the caliber of science that Raju brings to our team,” added Dr. Black.
During the webinar, Dr. Khatri will describe how to incorporate PRH effects on drug metabolism into ADME-Tox studies. He will also provide practical tips on how to use a SCHH model for CYP induction studies.